Immunovia AB (publ) (0G8X.L)
| Previous Close | 1.4680 |
| Open | 0.0000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 0.0000 - 0.0000 |
| 52 Week Range | |
| Volume | |
| Avg. Volume | 21,015 |
| Market Cap | 270,383 |
| Beta (5Y Monthly) | 2.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- PR Newswire
NOTICE OF ANNUAL GENERAL MEETING IN IMMUNOVIA AB (PUBL)
The shareholders in Immunovia AB (publ), Reg. No. 556730-4299, are hereby invited to the Annual General Meeting ("AGM") to be held at The Spark, Scheeletorget 1, Medicon Village, in Lund on Wednesday 19 June 2024 at 10 a.m. CEST.
- PR Newswire
Immunovia carries out a rights issue of units of approximately SEK 70 million and raises bridge loans
The Board of Directors of Immunovia AB (publ) ("Immunovia" or the "Company") has today, subject to approval by the Annual General Meeting on 19 June 2024, resolved to carry out an issue of shares and warrants ("units") with preferential rights for the Company's existing shareholders of initially approximately SEK 70 million (the "Rights Issue"). The Company has received subscription undertakings amounting to a total of approximately SEK 1.3 million, corresponding to approximately 2 percent of th
- PR Newswire
Immunovia streamlines lab operations with move to Research Triangle Park, North Carolina
Immunovia (NASDAQ Stockholm: IMMNOV), the diagnostics company seeking to increase pancreatic cancer survival through early detection, today announces that the company will move its lab and U.S. headquarters to Research Triangle Park in North Carolina in May 2024.
